Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario GuidelineN. Lynn Henry, Vered Stearns, Diana T. Chingos et al.|Journal of Clinical Oncology|2019Cited by 87
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).Lisa A. Carey, Clifford A. Hudis, Eric P. Winer et al.|Journal of Clinical Oncology|2014Cited by 24
Estrogen Receptor Genotypes, Menopausal Status, and the Effects of Tamoxifen on Lipid Levels: Revised and Updated ResultsDaniel F. Hayes, David A. Flockhart, Todd C. Skaar et al.|Clinical Pharmacology & Therapeutics|2010Cited by 16